Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Company Deals

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market

Fineline Cube Apr 14, 2026
Company Deals

Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech

Fineline Cube Apr 14, 2026
Company Deals

Zuellig Pharma Acquires Cialis Rights for Hong Kong, Macau, and South Korea from Eli Lilly

Fineline Cube Apr 14, 2026
Company Deals

Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration

Fineline Cube Apr 14, 2026
Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Fineline Cube Apr 14, 2026
Company Drug

Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion

Fineline Cube Apr 14, 2026
Company Drug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Fineline Cube Apr 14, 2026
Company Legal / IP R&D

Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology

Fineline Cube Sep 12, 2024

Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed...

Company Deals

Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization

Fineline Cube Sep 12, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...

Company Deals

Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy

Fineline Cube Sep 12, 2024

Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on...

Policy / Regulatory

China Aims to Fortify Insurance Industry by 2035 with New State Council Directives

Fineline Cube Sep 12, 2024

The State Council has issued the “Several Opinions on Strengthening Supervision, Preventing Risks, and Promoting...

Company Drug

Suzhou GenAssist Launches First-of-Its-Kind Base Editing Drug Trial for Duchenne Muscular Dystrophy

Fineline Cube Sep 12, 2024

Suzhou GenAssist Therapeutic Co., Ltd, a biopharmaceutical company based in China, has announced the commencement...

Company Medical Device

Siemens Healthineers’ 7T MRI System Terra. X Receives NMPA Marketing Approval

Fineline Cube Sep 12, 2024

Siemens Healthineers AG has secured marketing approval from China’s National Medical Products Administration (NMPA) for...

Company Drug

Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting

Fineline Cube Sep 12, 2024

Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...

Company Deals

CSA Medical Inc. Secures USD 53 Million in Series D Financing to Advance Cryotherapy Treatment

Fineline Cube Sep 11, 2024

CSA Medical Inc., a U.S.-based medical technology company, has successfully closed a Series D financing...

Company

Celltrion Inc. Enters CDMO Arena Amid Shifts in Global Biosecurity Landscape

Fineline Cube Sep 11, 2024

South Korea’s biosimilars giant, Celltrion Inc., is gearing up to expand into the contract development...

Company Deals

Gilead Sciences Partners with AI Firm Genesis Therapeutics to Develop Novel Small-Molecule Therapies

Fineline Cube Sep 11, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company based in the U.S., has entered into...

Company Deals

Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies

Fineline Cube Sep 11, 2024

Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage...

Company Deals

Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector

Fineline Cube Sep 11, 2024

Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Shows Promising Results in Phase II Study for ALK+ NSCLC

Fineline Cube Sep 11, 2024

Qilu Pharmaceutical, a leading pharmaceutical company based in China, has presented updated results from the...

Company Deals

ImmuneOnco Receives Second Payment from Instil Bio, Highlighting Ongoing Licensing Deal

Fineline Cube Sep 11, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the receipt of a further payment...

Company Drug

Nuance Pharma Completes Enrollment for Phase III COPD Trial of Ohtuvayre in China

Fineline Cube Sep 11, 2024

Nuance Pharma, a China-based pharmaceutical company, has announced the completion of patient enrollment for the...

Company Drug

Innovent Biologics Presents Promising Phase I Data for IBI363 in Advanced NSCLC at WCLC

Fineline Cube Sep 11, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has unveiled Phase...

Company Drug

Betta Pharmaceuticals’ MCLA129 for Advanced Solid Tumors Accepted for Review by China’s NMPA

Fineline Cube Sep 11, 2024

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a pharmaceutical company based in China, has announced that...

Company Drug

Duality Biologics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors

Fineline Cube Sep 11, 2024

Duality Biologics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with...

Company Medical Device

Medtronic Secures China Market Approval for Pulsed Electric Field Atrial Fibrillation Treatment Devices

Fineline Cube Sep 11, 2024

Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approvals...

Company Drug Legal / IP

AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute

Fineline Cube Sep 11, 2024

AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...

Posts pagination

1 … 283 284 285 … 650

Recent updates

  • Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion
  • China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access
  • Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion
  • China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program
  • CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion

Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Company Drug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.